Top

Administration and Policy in Mental Health and Mental Health Services Research

Published in:

01-05-2007 | Original Paper

The Relationship of Antipsychotic Medication Class and Adherence with Treatment Outcomes and Costs for Florida Medicaid Beneficiaries with Schizophrenia

Authors: Marion A. Becker, M. Scott Young, Ezra Ochshorn, Ronald J. Diamond

Published in: Administration and Policy in Mental Health and Mental Health Services Research | Issue 3/2007

Abstract

While some studies show a significant advantage in adherence rates with use of atypical versus typical antipsychotic medication, others show no advantage or mixed results (Jones et al. (2006). Archives of General Psychiatry, 63, 1079–1087; Rosenheck, (2006). Archives of General Psychiatry, 63, 1074–1076). This study examined treatment outcomes and costs associated with adherence rates by antipsychotic medication class for adult Medicaid beneficiaries in Florida diagnosed with schizophrenia. Outcomes examined include arrests, involuntary commitments, and physical and behavioral healthcare costs. Study findings demonstrate that medication adherence for persons with schizophrenia may be as important to treatment costs and benefits as the class of medication used.

Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005). Remission in schizophrenia: Proposed criteria and rationale for consensus. American Journal of Psychiatry, 162, 441–449.PubMedCrossRef

Awad, A. G., & Voruganti, L. N. (2004). New antipsychotics, compliance, quality of life, and subjective tolerability—Are patients better off? Canadian Journal of Psychiatry, 49(5), 297–302.

Baker, F. M., & Bell, C. (1999). Issues in the psychiatric treatment of African Americans. Psychiatric Services, 50(3), 362–350.PubMed

Becker, M., & Diamond, R. (2005). Quality of life measurement in persons with schizophrenia: Are we measuring what’s important? In H. Katschnig & H. Freeman (Eds.), Quality of life in mental disorders (2nd ed.). Chichester, England: Wiley.

Becker, M., Jang, Y., & Kane, M. (2006). Evaluation of Florida Medicaid behavioral health pharmacy practice by racial/ethnic minorities across the lifespan (pp. 1–27). Tampa, FL: Louis de la Parte Florida Mental Health Institute, University of South Florida.

Becker, M., & Lemrow, N. (2004). Behavioral health care services associated with switching atypical antipsychotic medication for persons with SMI (pp. 1–76). Tampa, FL: Louis de la Parte Florida Mental Health Institute, University of South Florida.

Boyd, D. L. (2003). The bursting State Fiscal Bubble and State Medical Budgets. Health Affairs, 22(1), 46–61.PubMedCrossRef

Brown, C., Markowitz, J., Moore, T., & Parker, N. (1999). Atypical antipsychotics, part II: Adverse effects, drug interactions, and costs. Annals of Pharmacotherapy, 33, 210–217.PubMedCrossRef

Csernansky, J. G., & Schuchart, E. K. (2002). Relapse and rehospitalisation rates in patients with schizophrenia: Effects of second generation antipsychotics. CNS Drugs, 16, 473–484.PubMedCrossRef

Daumit, G. L., Crum, R. M., Guallar, E., et al. (2003). Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and Whites in the United States. Archives of General Psychiatry, 60, 121–128.PubMedCrossRef

Davis, J. M., Chen, N., & Glick, I. D. (2003). A meta-analysis of the efficacy of second generation antipsychotics. Archive of General Psychiatry, 60, 553–564.CrossRef

Dolder, C. R., Lacro, J. P., Dunn, L. B., et al. (2002). Antipsychotic medication adherence: Is there a difference between typical and atypical agents? American Journal of Psychiatry, 159, 103–108.PubMedCrossRef

Dolder, C. R., Lacro, J. P., & Jeste, D. V. (2003). Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosomatic Medicine, 65, 156–162.PubMedCrossRef

Eaddy, M., Grogg, A., & Locklear, J. (2005). Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clinical Therapeutic, 27(2), 263–272.CrossRef

Fenton, W. S., Blyler, C. R., & Heinssen, R. K. (1997). Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin, 23(4), 637–651.PubMed

Fichtner, C. G., Hanrahan, P., & Luchins, D. J. (1998). Pharmacoeconomic studies of atypical antipsychotics: Review and perspective. Psychiatric Annals, 28(7), 381–396.

Foster, R. H., & Goa, K. L. (1999). Olanzapine: A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics, 15, 611–640.PubMedCrossRef

Gardner, J. C., Luo, Z., Bradley, C. J., Polverrjan, E., Holmes-Rovnes, M., & Rovner, D. (2003). Longitudinal assessment of cost in health care intervention. Health Services Research Methodology, 3, 149–168.CrossRef

Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000). Atypical antipsychotics in treatment of schizophrenia: Systematic overview and meta-regression analysis. British Nursing Journal, 321, 1371–1376.

Gibson, J., Damler, R., Jackson, A. E., Wilder, T., & Ramsey, J. L. (2004). The impact of olanzapine, risperidone, or haldol on the cost of schizophrenia care in a Medicaid population. Value in Health, 7(1), 22–35.PubMedCrossRef

Glazer, W. M. (1998). Formulary decisions and health economics. Journal of Clinical Psychiatry, 59(Suppl. 19), 23–29.PubMed

Hargraves, W. A., & Shumway, M. (1996). Pharmacoeconomics of antipsychotic drug therapy. Journal of Clinical Psychiatry, 57(Suppl. 9), 66–76.

Haynes, R. B. (1979). Introduction. In R. B. Haynes, D. L. Sackett, & D. W. Taylor (Eds.), Compliance in health care (pp. 1–10). Baltimore, MD: John Hopkins University Press.

Herbeck, D. M., West, J. C., Ruditis, I., et al. (2004). Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatric Services, 55, 677–684.PubMedCrossRef

Hogan, M. F. (1999). Public-sector mental health care: New challenges. Health Affairs, 18, 106–111.PubMedCrossRef

Javaid, J. I., Holland, D., & Janicak, P. G. (1991). Blood level monitoring of antipsychotics and antidepressants. Psychiatric Medicine, 9(1), 163–187.PubMed

Jones, K., Chen, H. J., Jordan, N., Boothroyd, R. A., Ramoni-Perazzi, J., & Shern, D. L. (2006). Examination of formal treatment costs in the provision of managed care for a Medicaid population with psychiatric disabilities. Medical Care, 44, 320–327.PubMedCrossRef

Jones, P., Barnew, T., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K., Murray, R., Markwick, A., & Lewis, S. (2006). Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Archives of General Psychiatry, 63, 1079–1087.PubMedCrossRef

Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. Journal of Clinical Psychiatry, 63(10), 892–909.PubMed

Lehman, A. F., & Steinwachs, D. M. (1998). Translating research into practice: the schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophrenia Bulletin, 24, 1–10.PubMed

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R., Perkins, D., Keefe, R., Davis, S., Davis, C., Lebowitz, B., Severe, J., & Hsiano, J. (2005). Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with schizophrenia. New England Journal of Medicine, 353, 1209–1223.PubMedCrossRef

McCombs, J. S., Nichol, M. B., Johnstone, B. M., Stimmel, G. L., Shi, J., & Smith, R. (2000). Antipsychotic drug use patterns and the cost of treating schizophrenia. Psychiatric Services, 51(4), 525–527.PubMedCrossRef

Mojtabai, R., Lavelle, J., Gibson, P.J., et al. (2002). Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989–1996. Psychiatric Services, 53(3), 337–339.PubMedCrossRef

Moy, E., Dayton, E., & Clancy, C. M. (2005). Compiling the evidence: The national healthcare disparities reports. Public Response, March/April, pp. 376–386.

Naber, D., Moritz, S., Lambert, M., et al. (2001). Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophrenia Research, 50, 79–88.PubMedCrossRef

Nicole, L. (2005). Health disparities—Less talk more action. New England Journal of Medicine, 35(7), 727–729.

Olivieri, N., Matsui, D., Hermann, C., & Koren, G. (1991). Compliance assessed by the medication event monitoring system. Archives of Disease in Childhood, 66, 1399–1402.PubMedCrossRef

Pandiana, J. A., & Banks, S. M. (2003). Large data sets are powerful. Psychiatric Services, 54, 745.CrossRef

Ren, X. S., Kazia, L. E., Lee, A. F., et al. (2002). Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. Journal of Pharmacy and Therapeutics, 27, 441–451.CrossRef

Rice, D. P. (1999). The economic impact of schizophrenia. Journal of Clinical Psychiatry, 60(Suppl. 1), 4–6.PubMed

Rittmannsberger, H., Pachinger, T., Keppelmuller, P., & Wancata, J. (2004). Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatric Services, 55(2), 174–179.PubMedCrossRef

Rosenheck, R. (2006). Outcomes, costs, and policy caution: A commentary on the cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry, 63, 1074–1076.PubMedCrossRef

Rosenheck, R., Perlick, D., Bingham, S., et al. (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. Journal of the American Medical Association, 290(20), 2693–2702.PubMedCrossRef

Schneider, E. C., Zaslavsky, A. M., & Epstein, A. M. (2002). Racial disparities in the quality of care for enrollees in medicare managed care. Journal of the American Medical Association, 287(10), 1288–1294.PubMedCrossRef

Shern, D., Robinson, P., Giard, J., & Vargo, A., et al. (2005). Evaluation of Florida’s Medicaid Managed Mental Health Plans: Year 8 Report Tampa, FL: Louis de la Parte Florida Mental Health Institute, University of South Florida.

Svarstad, B. L., Shireman, T. I., & Sweeney, J. K. (2001). Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services, 52, 805–811.PubMedCrossRef

Tandon, R. (1998). In conclusion, does antipsychotic treatment modify the long-term course of schizophrenic illness? Journal of Psychiatric Research, 32, 251–253.PubMedCrossRef

Thieda, P., Beard, S., Richter, A., & Kane, J. (2003). An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatric Services, 54(4), 508–516.PubMedCrossRef

Valenstein, M., Blow, F. C., Copeland, L. A., Mcarthy, J. F., et al. (2004). Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors. Schizophrenia Bulletin, 30(2), 255–264.PubMed

Vanelli, M., Burstein, P., & Crammer, J. (2001). Refill patterns of atypical and conventional antipsychotic medication at a national retail pharmacy chain. Psychiatric Services, 52, 1248–1250.PubMedCrossRef

Weiden, P., Aquila, R., & Standard, J. (1996). Atypical antipsychotic drugs and long-term outcome in schizophrenia. Journal of Clinical Psychiatry, 57(Suppl. ll), 53–60.PubMed

Weiden, P. J., Kozma, C., Grogg, A., & Locklear, J. (2004). Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services, 55(8), 886–891.PubMedCrossRef

Weiden, P. J., & Olfson, M. (1995). Cost of relapse in schizophrenia. Schizophrenia Bulletin, 21, 419–429.PubMed

Weiden, P., & Zygmunt, A. (1997). Medication noncompliance in schizophrenia. Part I. Assessment. Journal of Practical Psychiatry and Behavioral Health, 3, 106–110.

Wyatt, R. J., Henter, I., Leary, M. C., & Taylor, E. (1995). An economic evaluation of schizophrenia. Social Psychiatry and Psychiatric Epidemiology, 30, 196–205.PubMed

Ziguras, S. J., Klimidis, S., Lambert, T. J. R., & Jackson, A. C. (2001). Determinants of anti-psychotic medication compliance in a multicultural population. Community Mental Health Journal, 37(3), 273–283.PubMedCrossRef

Title: The Relationship of Antipsychotic Medication Class and Adherence with Treatment Outcomes and Costs for Florida Medicaid Beneficiaries with Schizophrenia
Authors: Marion A. Becker
M. Scott Young
Ezra Ochshorn
Ronald J. Diamond
Publication date: 01-05-2007
Publisher: Kluwer Academic Publishers-Plenum Publishers
Published in: Administration and Policy in Mental Health and Mental Health Services Research / Issue 3/2007
Print ISSN: 0894-587X
Electronic ISSN: 1573-3289
DOI: https://doi.org/10.1007/s10488-006-0108-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Relationship of Antipsychotic Medication Class and Adherence with Treatment Outcomes and Costs for Florida Medicaid Beneficiaries with Schizophrenia

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2007

Developing Strategies to Integrate Peer Providers into the Staff of Mental Health Agencies

Administrative Barriers to the Adoption of High-Quality Mental Health Services for Children in Foster Care: A National Study

Organizational and Individual Factors Affecting Consumer Outcomes of Care in Mental Health Services

Empirical Evaluation of the Generalizability of the Sample from the Multimodal Treatment Study for ADHD

A Population-based Needs Assessment for Mental Health Services

A Competency-Based Approach to Managing Violence with Involuntary Outpatient Treatment